The present invention relates to anti-α-synuclein antibodies, which preferentially recognize α-synuclein aggregates, and uses for detection, diagnosis, and/or treatment or prevention of a variety of diseases or disease symptoms related thereto due to accumulation of α-synuclein aggregates by using the anti-α-synuclein antibodies.